Monday, July 13, 2026

pharma · Nasopharyngeal Carcinoma · Hepatocellular Carcinoma

Chinese Academy of

Chinese Academy of is a pharma organization headquartered in TAIZHOU, CN. Primary therapeutic focus areas include Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, COVID-19, Breast Cancer, Coronary Artery Disease. Nova

China, TAIZHOU, CN HQ
170 Employees
NMPA registrant Type
Company details
Status
Public
HQ
China, TAIZHOU, CN
Employees
170
Programs
1328
Drugs
711
Patents
335
Clinical program

recombinant human erythropoietin

Approved · small molecule · Premature Birth

recombinant human erythropoietin for Premature Birth is a Approved program (small_molecule) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).

Internal code CZZ-EPO

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase
Approved
Modality
small_molecule
Indication
Premature Birth
Status
completed
Trials
1